IFP Advisors’s TherapeuticsMD TXMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$46 Hold
21
﹤0.01% 5032
2026
Q1
$42 Hold
21
﹤0.01% 4852
2025
Q4
$34 Hold
21
﹤0.01% 4751
2025
Q3
$23 Hold
21
﹤0.01% 4747
2025
Q2
$24 Hold
21
﹤0.01% 4840
2025
Q1
$19 Sell
21
-59
-74% -$59 ﹤0.01% 4171
2024
Q4
$69 Hold
80
﹤0.01% 4159
2024
Q3
$133 Hold
80
﹤0.01% 3224
2024
Q2
$129 Buy
80
+20
+33% +$40 ﹤0.01% 3160
2024
Q1
$137 Buy
+60
New +$139 ﹤0.01% 3048
2023
Q3
Sell
-16
Closed -$66 3554
2023
Q2
$66 Hold
16
﹤0.01% 3372
2023
Q1
$77 Buy
+16
New +$77 ﹤0.01% 3316
2019
Q1
Sell
-20
Closed -$4K 3385
2018
Q4
$4K Sell
20
-2
-9% -$488 ﹤0.01% 2965
2018
Q3
$7K Hold
22
﹤0.01% 3072
2018
Q2
$7K Sell
22
-10
-31% -$3.06K ﹤0.01% 3113
2018
Q1
$10K Hold
32
﹤0.01% 2801
2017
Q4
$10K Sell
32
-74
-70% -$20.6K ﹤0.01% 2842
2017
Q3
$28K Sell
106
-22
-17% -$6.36K ﹤0.01% 2390
2017
Q2
$34K Sell
128
-2
-2% -$501 ﹤0.01% 2237
2017
Q1
$47K Sell
130
-4
-3% -$1.24K ﹤0.01% 1972
2016
Q4
$39K Buy
134
+120
+857% +$37.2K ﹤0.01% 2030
2016
Q3
$5K Sell
14
-2
-13% -$730 ﹤0.01% 3258
2016
Q2
$7K Buy
+16
New +$6.59K ﹤0.01% 2963

Other funds holding TXMD

IFP Advisors's TXMD Position: Q2 2026 in Review

IFP Advisors held its TherapeuticsMD (TXMD) position steady in Q2 2026 at 21 shares worth $46. The position accounts for ﹤0.01% of the portfolio, ranked #5032.

IFP Advisors first reported a position in TXMD in Q2 2016 and has held it in 23 quarters since. The position peaked at $47K in Q1 2017. 9 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • IFP Advisors held 21 shares of TherapeuticsMD worth $46 as of Q2 2026.
  • IFP Advisors left its TherapeuticsMD share count unchanged in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5032 holding.
  • IFP Advisors first reported a position in TherapeuticsMD in Q2 2016 and has held it in 23 quarters since.
  • IFP Advisors's TherapeuticsMD position peaked at $47K in Q1 2017.
  • 9 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.